Celldex Presents Positive Results from Phase 2 Study of ADC Product Candidate CDX-011 in Breast Cancer
News Dec 15, 2009
Celldex Therapeutics, Inc. has announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.
As presented the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, the primary efficacy endpoint for the study has been met with significant antitumor activity in patients whose tumors express the target GPNMB.
In addition, encouraging results were seen in patients with “triple-negative disease” where treatment options are relatively limited due to lack of hormone receptor or HER2-neu expression.
CDX-011 is the first candidate from the Company’s antibody-drug conjugate (ADC) platform, which utilizes fully human monoclonal antibodies to deliver the potent cellular toxin, MMAE, directly to tumor cells by targeting GPNMB.
GPNMB is a glycoprotein frequently expressed in a number of tumor types and associated with cancer progression and recurrence. CDX-011 uses the Seattle Genetics MMAE ADC technology, which has established a very promising antitumor effect in advanced clinical studies.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE